KOD
Kodiak Sciences Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 31 ▲ Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), m…
- May 11 Trial readout: T-90d Trial Readout: Tarcocimab tedromer (Phase 3)
- May 13 Trial readout: Results Pending: Tarcocimab (Phase 3), Completed 89d ago
- May 18 Trial readout: T-90d Trial Readout: Tarcocimab tedromer (Phase 3)
- Aug 13 Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), w…
- Sep 28 to Sep 29 ▲ 2 days of insider buys: $51.8M by 1 insider, avg $82.87
- Sep 28 ▲ Kodiak Sciences announced positive topline Phase 3 DAYBREAK results…
- Sep 30 ▲ Baker Bros. Advisors LP filed Amendment No. 12 to its Schedule 13D f…
- Oct 21 ▼ 1 insider sell $2.7M at $90.01
- Nov 4 to Nov 5 ▲ 2 days of insider buys: $24.3M by 1 insider, avg $98.51
- Nov 12 ▲ Kodiak Sciences reported Q3 2026 results with a net loss of $66.2M (…
- Nov 12 ▲ Earnings: KOD Q3 2026 Earnings: EPS $-1.05 (+2.1% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $76.1M at an average $87.30. 1 insider sold $2.7M. Price is 15% above their cost.
- InstitutionsBULLISH
Q2 2026: 27 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
9 of 11 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.996 → −$0.984 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −4.5% to 8.12M shares. 9.3 days to cover, ≈12.9% of shares.
- TrendUPTREND
29% above its 50-day average. New closing high $111.19 on Nov 13.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 9.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $126.6M |
| GOLDMAN SACHS GROUP INC | ADD | $90.2M |
| Artisan Partners Limited Partnership | ADD | $37.7M |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | $30.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $20.8M |
| BANK OF AMERICA CORP /DE/ | ADD | $14.9M |
| FMR LLC | ADD | $10.8M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $7.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +28%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | UBS MAINTAIN | Buy |
| Oct 12, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 28, 2026 | LifeSci Capital MAINTAIN | Outperform |
| Sep 28, 2026 | UBS MAINTAIN | Buy |
| Sep 28, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 17, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
BAKER BROS. ADVISORS LP Director Nov 5, 2026 | BUY | $8.1M |
BAKER BROS. ADVISORS LP Director Nov 5, 2026 | BUY | $463.3K |
BAKER BROS. ADVISORS LP Director Nov 4, 2026 | BUY | $861.2K |
BAKER BROS. ADVISORS LP Director Nov 4, 2026 | BUY | $15.0M |
Yang Taiyin Director Oct 23, 2026 | EXERCISE | $47.0K |
BORGESON JOHN A. Chief Financial Officer Oct 21, 2026 | EXERCISE | $74.7K |
BORGESON JOHN A. Chief Financial Officer Oct 21, 2026 | SELL | $746.4K |
BORGESON JOHN A. Chief Financial Officer Oct 21, 2026 | SELL | $149.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.98 | -$1.05–-$0.93 | -0.0% | $0.00 |
| Next Q | -$1.16 | -$1.16–-$1.16 | No data | $0.00 |
| Current FY | -$4.03 | -$4.09–-$3.99 | -1.2% | $0.00 |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 7 bullish · 3 bearish · 3 neutral- BEARISH SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 4.7% passive stake in Kodiak Sciences as of September 30, 2026, down from a prior 5%+ position. The reduction below the 5% threshold signals a significant exit by a former top holder.
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 16, 2026
Sirenia Capital Management LP filed an amended Schedule 13G disclosing a 2.9% passive stake in Kodiak Sciences as of September 30, 2026, down from a prior 5%+ position. The reduction below the 5% threshold signals a significant exit by a former top holder.
🔒 Fresh report (last 24h), subscribers only
- BULLISH 8-KNov 12, 2026
Kodiak Sciences reported Q3 2026 results with a net loss of $66.2M ($1.05/share), wider than the…
The DAYBREAK success de-risks the Zenkuda BLA submission due by year-end, but the rapid cash burn and thin equity base ($12.6M) mean the company will likely need additional capital before reaching…
- BULLISH INSIDER-BUYNov 6, 2026
Baker Bros. Advisors LP, a director and 10% owner, purchased 8,742 shares of Kodiak Sciences at…
Baker Bros., the largest shareholder, has been aggressively accumulating shares this week with no 10b5-1 plan, signaling strong conviction. Monitor for any upcoming corporate catalysts such as trial…
All KOD filing & press-release reports (13)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 12, 2026
- INSIDER-BUY reportNov 6, 2026
- S-3ASR reportOct 20, 2026
- SC 13D/A reportSep 30, 2026
- INSIDER-BUY reportSep 30, 2026
- 8-K reportSep 28, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 7, 2026
- 8-K reportMar 31, 2026